The Sepsis Market 2003 - Can Analyst Expectation be Met?

Introduction

The launch, and disappointing sales, of Lilly’s sepsis treatment, Xigris (drotrecogin alpha), has emphasized the complexity of the sepsis market, acting as a wake-up call for companies involved in the development and marketing of sepsis treatments. 

Scope

An overview of the epidemiological and patient segmentation for sepsis across the US, Europe and Japan. 

Diagnostic techniques and disease evaluation systems are critically reviewed. 

Current treatment practices and guidelines are examined, highlighting the remaining unmet need. 

Lilly’s Xigris is profiled with projections for future performance. 

Report Highlights

Incidence of sepsis continues to rise across the developed world, with US increases of 1.5% per annum expected until 2020. However, tapping this huge patient potential will require a product with significantly fewer contraindications than Lilly’s Xigris, which has failed to meet analyst expectation. 

Patients presenting with sepsis are admitted to the ICU via a variety of routes, leading to significant variation in the level, timing and quality of care. Companies marketing sepsis therapies will need to establish sales infrastructure capable of targeting, and educating, across multiple hospital units if maximum market potential is to be tapped. 

Improvement in 28-day mortality has, to date, been used as the primary end point in all clinical trials for sepsis therapies. Although this is still considered essential, companies should also investigate and promote the long-term benefits of sepsis therapies in terms of cost savings and quality of life. 

Reasons to Purchase

Understand the epidemiology of sepsis across the US, Europe and Japan 

Target sepsis promotional strategies more appropriately 

Identify the key limitations of current sepsis treatments and predict the performance of Xigris 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a170